Cellectis Reports Preliminary Results from its Phase 1 BALLI-01 Study of UCART22 in R/R Adult B-ALL at American Society of Hematology (ASH) Annual MeetingGlobeNewsWire • 12/05/20
FDA Lifts Clinical Hold on MELANI-01 Study Evaluating Cellectis' Product Candidate UCARTCS1 in Multiple MyelomaGlobeNewsWire • 11/18/20
Cellectis Appoints Pharma HR Leader Kyung Nam-Wortman as Executive Vice President, Chief Human Resources OfficerGlobeNewsWire • 11/16/20
Cellectis' (CLLS) CEO André Choulika on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/06/20
Cellectis Provides Business Update and Reports Financial Results for Third Quarter and First Nine Months 2020GlobeNewsWire • 11/05/20
American Society of Hematology (ASH) Abstract Shows Initial Anti-Leukemic Activity of UCART22 in BALLI-01 Phase 1 Study in R/R Adult B-ALLGlobeNewsWire • 11/04/20
Cellectis to Hold Third Quarter 2020 Earnings Call on Friday, November 6, 2020 at 8:00AM ESTGlobeNewsWire • 10/21/20
Cellectis S.A. (CLLS) CEO André Choulika on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/06/20
Cellectis Provides Business Update and Reports Financial Results for Second Quarter and First Six Months 2020GlobeNewsWire • 08/05/20
Cellectis to Hold Second Quarter 2020 Earnings Call on Thursday, August 6, 2020 at 7:30AM EDTGlobeNewsWire • 07/29/20
Cellectis Appoints Biopharma Veteran Steve Doares, Ph.D., as Senior Vice President of US ManufacturingGlobeNewsWire • 07/21/20
To Fully Focus on Cellectis, Dr. André Choulika Retires From Calyxt’s Board of DirectorsGlobeNewsWire • 07/06/20
Is Cellectis (CLLS) Outperforming Other Medical Stocks This Year?Zacks Investment Research • 06/30/20
Cellectis S.A. Reports Results from Annual Shareholders’ General Meeting Held on June 29, 2020GlobeNewsWire • 06/29/20
Cellectis Published Streamlined Manufacturing Method to Generate Ultrapure Allogeneic CAR T-Cell TherapiesGlobeNewsWire • 06/25/20